邓文宏
普外
主任医师，博士生导师，科副主任，副教授
主任医师，博士生导师，科副主任，副教授
导师介绍
| 姓名 | 邓文宏 |
| 出生年月 | 1984年10月 |
| 单位 | 武汉大学人民医院胃肠外科 |
| 所属学科 | 临床医学-外科学 |
| 职务、职称及头衔 | 主任医师，博士生导师，科副主任，副教授 |
| wenhongdeng@whu.edu.cn | |
| 联系方式 | 027-88041911转83350 |
| 研究方向 |
1.胃肠道免疫相关疾病 2.消化系统内分泌及神经体液调节异常 3.胃肠道及腹腔感染性疾病 4.胰腺外分泌功能异常与胰腺炎 5.衰老相关疾病神经内分泌免疫异常 6.肿瘤学研究与其他学科交叉 7.肿瘤免疫治疗 8.基于特殊临床特征的肿瘤研究 |
| 个人简介 | 主要从事胃肠道疾病诊治与科研工作，主持国家自然科学基金2项、湖北省自然科学面上项目1项。参与国家自然科学基金、湖北省科技厅、省卫生厅课题共计5项。参编著作《急诊医学技术与临床实践》，在《Clinical Nutrition》、《Biomedicine & Pharmacotherapy》、《Journal of Translational Medicine》、《中华胃肠外科杂志》等杂志上发表论文100余篇，以第一作者或通讯作者发表论文40余篇，其中SCI论文近30篇，影响因子超过100。已培养硕士生3名。国家公派留学美国加州大学洛杉矶分校，第七批武汉市中青年医学骨干人才，武汉大学人民医院第五轮重点青年培养人才。 |
| 学术任职与荣誉 |
中华医学会肠外肠内营养学分会(CSPEN)青年学组委员 中国抗癌协会肿瘤胃肠病专业委员会青年联盟委员 中国国家科技专家库成员 湖北省医师协会第一届微无创医学专业委员会委员 湖北省科学技术厅专家库成员 湖北省微循环学会功能性胃肠外科专委会委员 湖北省微循环学会减重外科与代谢外科专委会常务委员 湖北省临床肿瘤学会第一届青年专家委员会委员 武汉医学会普外分会减重代谢学组委员 武汉医学会普外分会肛肠学组委员 《中国普通外科学杂志》编委 湖北省微循环学会理事会理事 |
| 教育履历 |
2003.09-2008.06西南医科大学临床医学专业本科生获学士学位 2008.09-2013.06武汉大学第一临床学院外科学硕博连研究生获博士学位 |
| 工作履历 |
2013.07-2013.11武汉大学人民医院胃肠外科住院医师 2013.11-2017.11武汉大学人民医院胃肠外科主治医师 2017.11-2022.11武汉大学人民医院胃肠外科副主任医师 2019.06-2020.06 美国加州大学洛杉矶分校访问学者 2019-06-2020.06, University of Charles R Drew查尔斯大学癌症研究中心博士后 2020.10-至今，武汉大学人民医院，硕士生导师 2021.11-至今，武汉大学人民医院，副教授 2022.11-至今，武汉大学人民医院东院胃肠外科，主任医师 2024.06-至今，武汉大学人民医院，博士生导师 |
| 成果获奖 | 武汉大学优秀教学研究论文三等奖 |
| 代表性论著 |
1. Wu Z, Zhang L, Li X, Liu L, Kuang T, Qiu
Z, Deng W, Wang W. The prognostic significance and potential mechanism of
DBF4 zinc finger in hepatocellular carcinoma. Sci Rep. 2024 May
9;14(1):10662. 2. Lilong Z, Kuang T, Li M, Li X, Hu P, Deng W, Wang W. Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers. Clin Nutr. 2024 Jan;43(1):31-41. 3. Liu L, Zhang L, Li C, Qiu Z, Kuang T, Wu Z, Deng W. Effects of hormones on intestinal stem cells. Stem Cell Res Ther. 2023 Apr 26;14(1):105. 4. Zhang L, Chen C, Chai D, Li C, Qiu Z, Kuang T, Liu L, Deng W, Wang W. Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma. J Transl Med. 2023 Feb 15;21(1):126. 5. Zhang L, Zhao K, Kuang T, Wang K, Chai D, Qiu Z, Liu R, Deng W, Wang W. The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy. BMC Cancer. 2023 Jan 30;23(1):101. 6. Zhang L, Chen C, Chai D, Li C, Guan Y, Liu L, Kuang T, Deng W, Wang W. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. Front Immunol. 2022 Aug 17;13:956533. 7. Zhang L, Jin Q, Chai D, Kuang T, Li C, Guan Y, Liu L, Wang W, Deng W. The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors. Front Pharmacol. 2022 Aug 30;13:937874. 8. Deng W, Li J, Dorrah K, Jimenez-Tapia D, Arriaga B, Hao Q, Cao W, Gao Z, Vadgama J, Wu Y. The role of PPM1D in cancer and advances in studies of its inhibitors. Biomed Pharmacother. 2020 May;125:109956. |
| Name | DENG WENHONG |
| Date of birth | October，1984 |
| Department | Gastrointestinal Surgery Department，Renmin Hospital,Wuhan University. |
| Title | Chief Physician, Doctoral tutor，Deputy Director , Associate Professor |
| wenhongdeng@whu.edu.cn | |
| TEL | 027-88041911-83350 |
| Research Direction |
1.
gastrointestinal immune-related diseases 2. digestive endocrine and neurohumoral regulatory abnormalities 3. gastrointestinal and abdominal infectious diseases 4. pancreatic exocrine function abnormalities and pancreatitis 5. neuroendocrine immune abnormalities in ageing-related diseases 6. oncology research at the intersection of other disciplines 7. immunotherapy of tumours 8. oncology research based on specific clinical features |
| Personal Profile | He is mainly engaged in the diagnosis and treatment of gastrointestinal diseases and scientific research, and has presided over two projects of the National Natural Science Foundation of China (NSFC), and one project of the Natural Science Surface Program of Hubei Province. He has participated in 5 projects of National Natural Science Foundation of China, Hubei Provincial Science and Technology Department and Provincial Health Department. He has published more than 100 papers in Clinical Nutrition, Biomedicine & Pharmacotherapy, Journal of Translational Medicine, BMC Cancer, Chinese Journal of Gastrointestinal Surgery and other journals, and more than 40 papers as the first or corresponding author, of which nearly 30 papers are SCI papers with an impact factor of more than 100. He has trained 3 master students. He is a national scholarship student at UCLA, the seventh batch of Wuhan young and middle-aged medical backbone talents, and the fifth round of key young training talents of Wuhan University People's Hospital. |
| Selected Publications |
1. Wu Z, Zhang L, Li X, Liu L, Kuang T, Qiu
Z, Deng W, Wang W. The prognostic significance and potential mechanism of
DBF4 zinc finger in hepatocellular carcinoma. Sci Rep. 2024 May
9;14(1):10662. 2. Lilong Z, Kuang T, Li M, Li X, Hu P, Deng W, Wang W. Sarcopenia affects the clinical efficacy of immune checkpoint inhibitors in patients with gastrointestinal cancers. Clin Nutr. 2024 Jan;43(1):31-41. 3．Liu L, Zhang L, Li C, Qiu Z, Kuang T, Wu Z, Deng W. Effects of hormones on intestinal stem cells. Stem Cell Res Ther. 2023 Apr 26;14(1):105. 4. Zhang L, Chen C, Chai D, Li C, Qiu Z, Kuang T, Liu L, Deng W, Wang W. Characterization of the intestinal fungal microbiome in patients with hepatocellular carcinoma. J Transl Med. 2023 Feb 15;21(1):126. 5. Zhang L, Zhao K, Kuang T, Wang K, Chai D, Qiu Z, Liu R, Deng W, Wang W. The prognostic value of the advanced lung cancer inflammation index in patients with gastrointestinal malignancy. BMC Cancer. 2023 Jan 30;23(1):101. 6. Zhang L, Chen C, Chai D, Li C, Guan Y, Liu L, Kuang T, Deng W, Wang W. The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors. Front Immunol. 2022 Aug 17;13:956533. 7. Zhang L, Jin Q, Chai D, Kuang T, Li C, Guan Y, Liu L, Wang W, Deng W. The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors. Front Pharmacol. 2022 Aug 30;13:937874. 8. Deng W, Li J, Dorrah K, Jimenez-Tapia D, Arriaga B, Hao Q, Cao W, Gao Z, Vadgama J, Wu Y. The role of PPM1D in cancer and advances in studies of its inhibitors. Biomed Pharmacother. 2020 May;125:109956. |
武汉大学人民医院
湖北省人民医院